

Vaccine Prize Winners, CureVac, to Present at Cancer Vaccines 2014

CureVac GmbH win a \$2.7 million vaccine prize from the European Commission

LONDON, LONDON, UNITED KINGDOM, June 26, 2014 /EINPresswire.com/ -- CureVac GmbH recently won a \$2.7 million vaccine prize from the European Commission for developing prophylactic vaccines that can reach remote areas in the world without the need for cooling. In a statement released last month, Ingmar Hoerr, CEO and co-founder of CureVac, said:

“We are extremely honored that the jury has recognized our results of more than 14 years development of RNActive vaccines as the biggest leap forward in vaccine technology” [*Source](#)

Hear more from CureVac when Program Management Oncology Director, Dr Birgit Scheel, presents on cancer immunotherapy at SMI’s 3rd annual [Cancer Vaccines](#) conference taking place on 15th and 16th September in London, UK.



We are extremely honored that the jury has recognized our results of more than 14 years development of RNActive vaccines as the biggest leap forward in vaccine technology”

CureVac

With a focus on RNActive®, CureVac will be sharing their insights in a unique presentation entitled: RNActive® for Cancer Immunotherapy. Harnessing the natural power of the immune system to fight the disease and updates on current trials will be just some of the topics addressed by Dr Scheel.

Targeted towards an audience of oncolytic vaccine developers, Cancer Vaccines 2014 will cover sessions on oncolytic vaccines, T cell immune monitoring, cancer

immunotherapy, biomarker guided development and future progress.

Key Speakers Include:



- Joseph Melenhorst, Director of the Product Development & Correlative Sciences laboratory, University Of Pennsylvania
- Tom Lillie, Therapeutic Area Head, Oncology, Amgen Ltd
- Alex Karlsson-Parra, CSO, Immunicum AB
- Harpreet Singh, Managing Director, Founder and CSO, Immatics Biotechnologies GmbH
- Christian Ottensmeier, Professor in Experimental Cancer Medicine, University Of Southampton
- Madiha Derouazi, CEO, Amal Therapeutics
- Eric Leire, CEO, DanDrit Biotech

For those who are interested, early bird discounts are currently available with a deadline of 30th June. Recent confirmed booking include: Theravectys, Breast International Group, XEME Biopharma, Boehringer Ingelheim. For further details and to see the full speaker line-up, visit www.cancer-vaccineevent.com

3rd annual conference on:
Cancer Vaccines

Assess and Quantify Strategies to Enhance Cancer Vaccine Research and Development
15 - 16 September 2014 | Holiday Inn Regents Park, London UK

www.cancer-vaccineevent.com

Sponsored by Immudex and Scancell

-----end-----

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/211142720>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.